HIV protease inhibitors, indinavir or nelfinavir, augment antimalarial action of artemisinin in vitro. 2010

Lokesh C Mishra, and Amit Bhattacharya, and Manish Sharma, and Virendra K Bhasin
Department of Zoology, University of Delhi, Delhi, India. lokesh20sept@yahoo.co.in

Most malaria endemic regions are co-infested with HIV infection. Treatment of one may affect outcome of the other in co-infected individuals. HIV protease inhibitors, indinavir or nelfinavir, are important antiretroviral drugs and artemisinin is central to malaria treatment. We show these protease inhibitors augment the antimalarial activity of artemisinin against P. falciparum in vitro.

UI MeSH Term Description Entries
D008288 Malaria A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia. Marsh Fever,Plasmodium Infections,Remittent Fever,Infections, Plasmodium,Paludism,Fever, Marsh,Fever, Remittent,Infection, Plasmodium,Plasmodium Infection
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000962 Antimalarials Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) Anti-Malarial,Antimalarial,Antimalarial Agent,Antimalarial Drug,Anti-Malarials,Antimalarial Agents,Antimalarial Drugs,Agent, Antimalarial,Agents, Antimalarial,Anti Malarial,Anti Malarials,Drug, Antimalarial,Drugs, Antimalarial
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV
D019469 Indinavir A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. Crixivan,Indinavir Sulfate,Indinavir, Sulfate (1:1),L-735 524,L-735,524,MK-639,L 735 524,L 735,524,L735 524,L735,524,MK 639,MK639,Sulfate, Indinavir
D019888 Nelfinavir A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. AG 1343,AG-1343,AG1343,Nelfinavir Mesylate,Nelfinavir Monomethane Sulfonate,Viracept,Mesylate, Nelfinavir,Monomethane Sulfonate, Nelfinavir,Sulfonate, Nelfinavir Monomethane
D037621 Artemisinins A group of SESQUITERPENES and their analogs that contain a peroxide group (PEROXIDES) within an oxepin ring (OXEPINS).

Related Publications

Lokesh C Mishra, and Amit Bhattacharya, and Manish Sharma, and Virendra K Bhasin
February 2004, Organic & biomolecular chemistry,
Lokesh C Mishra, and Amit Bhattacharya, and Manish Sharma, and Virendra K Bhasin
November 2002, Pharmaceutical research,
Lokesh C Mishra, and Amit Bhattacharya, and Manish Sharma, and Virendra K Bhasin
January 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences,
Lokesh C Mishra, and Amit Bhattacharya, and Manish Sharma, and Virendra K Bhasin
October 2002, Journal of pharmaceutical and biomedical analysis,
Lokesh C Mishra, and Amit Bhattacharya, and Manish Sharma, and Virendra K Bhasin
May 2001, Journal of chromatography. B, Biomedical sciences and applications,
Lokesh C Mishra, and Amit Bhattacharya, and Manish Sharma, and Virendra K Bhasin
September 2001, Antiviral therapy,
Lokesh C Mishra, and Amit Bhattacharya, and Manish Sharma, and Virendra K Bhasin
July 2001, AIDS (London, England),
Lokesh C Mishra, and Amit Bhattacharya, and Manish Sharma, and Virendra K Bhasin
April 1999, Journal of chromatography. B, Biomedical sciences and applications,
Lokesh C Mishra, and Amit Bhattacharya, and Manish Sharma, and Virendra K Bhasin
January 2012, Journal of neurochemistry,
Lokesh C Mishra, and Amit Bhattacharya, and Manish Sharma, and Virendra K Bhasin
June 2001, Journal of chromatography. B, Biomedical sciences and applications,
Copied contents to your clipboard!